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Foundation,	and	Sigrid	Jusélius	Foundation.	Dr.	Mertz	was	a	recipient	of	
a	Research	Early	Career	Award	from	Hamilton	Health	Sciences	Founda-
tion	(Jack	Hirsh	Fellowship).	Dr.	Bassler	is	employed	by	the	University	of	
Zurich.	His	institution	received	grant	support	from	a	FP7	grant.	Dr.	Busse	
was	 funded	by	 a	New	 Investigator	Award	 from	 the	Canadian	 Institutes	
of	 Health	 Research	 and	 Canadian	 Chiropractic	 Research	 Foundation.	
He	 received	 support	 for	 article	 research	 from	 the	 Swiss	 National	 Sci-
ence	Foundation	(grant	320030_133540/1)	and	the	German	Research	
Foundation	 (grant	EL	544/1–2).	Dr.	Ferreira-González	 received	support	
for	the	development	of	educational	presentations	from	Bayer	and	Abbot.	
His	institution	received	grant	support	from	Spanish	Health	Institute	Car-
los	III.	Drs.	Nordmann,	Gloy,	and	Raatz	were	supported	by	Santésuisse	
and	 the	Gottfried	and	Julia	Bangerter-Rhyner-Foundation.	Dr.	Rosenthal	
is	an	employee	of	F.	Hoffmann-La	Roche	Ltd.	since	May	01,	2014.	The	
present	study	was	conducted	before	Dr.	Rosenthal	 joined	F.	Hoffmann-
La	Roche	 Ltd.	 and	 has	 no	 connection	 to	 her	 employment	 by	 the	 com-
pany.	Dr.	Hemkens	was	supported	by	Santésuisse	and	the	Gottfried	and	
Julia	Bangerter-Rhyner-Foundation.	Dr.	Cook	 is	a	Research	Chair	of	 the	
Canadian	 Institutes	 of	 Health	 Research.	 Dr.	 Bucher	 was	 supported	 by	
Santésuisse	 and	 the	 Gottfried	 and	 Julia	 Bangerter-Rhyner-Foundation.	
Dr.	Kasenda’s	institution	received	grant	support.	Dr.	Briel	was	supported	
by	Santésuisse	and	the	Gottfried	and	Julia	Bangerter-Rhyner-Foundation.	
Drs.	Gloy,	Raatz,	Hemkens,	Bucher,	and	Briel’s	institutions	received	grant	
support	 from	 the	 Swiss	 National	 Science	 Foundation.	 The	 remaining	
authors	 have	disclosed	 that	 they	do	not	 have	 any	potential	 conflicts	 of	
interest.	 These	 funding	 agencies	 had	 no	 role	 in	 the	 design	 or	 conduct	
of	 the	study,	 including	but	not	 limited	 to,	study	 identification,	collection,	 
management,	 analysis,	 and	 interpretation	 of	 the	 data	 or	 preparation,	
review,	or	approval	of	the	final	report.
For	information	regarding	this	article,	E-mail:	Matthias.Briel@usb.ch
Objectives:	Randomized	clinical	trials	that	enroll	patients	in	critical	
or	emergency	care	(acute	care)	setting	are	challenging	because	
of	narrow	time	windows	for	recruitment	and	the	inability	of	many	
patients	 to	provide	 informed	consent.	To	assess	 the	extent	 that	
recruitment	challenges	lead	to	randomized	clinical	trial	discontinu-
ation,	we	compared	 the	discontinuation	of	acute	care	and	non-
acute	care	randomized	clinical	trials.
Design:	 Retrospective	 cohort	 of	 894	 randomized	 clinical	 trials	
approved	by	six	institutional	review	boards	in	Switzerland,	Germany,	
and	Canada	between	2000	and	2003.
Setting:	Randomized	clinical	trials	involving	patients	in	an	acute	or	
nonacute	care	setting.
Subjects and Interventions:	 We	 recorded	 trial	 characteristics,	
self-reported	 trial	 discontinuation,	 and	 self-reported	 reasons	
for	 discontinuation	 from	 protocols,	 corresponding	 publications,	 
institutional	review	board	files,	and	a	survey	of	investigators.
Measurements and Main Results:	Of	894	randomized	clinical	trials,	
64	(7%)	were	acute	care	randomized	clinical	trials	(29	critical	care	
and	35	emergency	care).	Compared	with	the	830	nonacute	care	
randomized	clinical	trials,	acute	care	randomized	clinical	trials	were	
more	frequently	discontinued	(28	of	64,	44%	vs	221	of	830,	27%;	 
p	=	0.004).	Slow	recruitment	was	the	most	 frequent	reason	for	
discontinuation,	both	in	acute	care	(13	of	64,	20%)	and	in	non-
acute	 care	 randomized	 clinical	 trials	 (7	 of	 64,	 11%).	 Logistic	
regression	analyses	suggested	the	acute	care	setting	as	an	inde-
pendent	 risk	 factor	 for	 randomized	 clinical	 trial	 discontinuation	
specifically	as	a	result	of	slow	recruitment	(odds	ratio,	4.00;	95%	
CI,	1.72–9.31)	after	adjusting	 for	other	established	risk	 factors,	
including	nonindustry	sponsorship	and	small	sample	size.
Conclusions:	Acute	care	randomized	clinical	trials	are	more	vul-
nerable	 to	 premature	 discontinuation	 than	 nonacute	 care	 ran-
domized	clinical	trials	and	have	an	approximately	four-fold	higher	
risk	 of	 discontinuation	 due	 to	 slow	 recruitment.	 These	 results	
highlight	the	need	for	strategies	to	reliably	prevent	and	resolve	
slow	patient	recruitment	in	randomized	clinical	trials	conducted	
in	the	critical	and	emergency	care	setting.	(Crit Care Med	2016;	
44:130–137)
Key Words:	critical	care;	early	termination	of	clinical	trials;	emergency	
medicine;	ethics	committees;	randomized	controlled	trials
Randomized clinical trials (RCTs) enrolling patients who are acutely ill in the critical care or emergency care (acute care) setting are particularly challenging. 
One difficulty concerns the informed consent that is typically 
sought from substitute decision makers who are not always 
available or are difficult to identify (1). When substitute deci-
sion makers are available, they are often overwhelmed and 
under stress because of the need to decide rapidly on poten-
tially life-saving interventions (1). Narrow time windows also 
challenge the recruiting staff who must quickly identify eligible 
patients and initiate study procedures (2). Another barrier to 
efficient recruitment can be the prohibition of coenrollment of 
patients into more than one RCT by protocols, physicians, or 
institutional review boards (IRBs) (1). Finally, decision making 
in multidisciplinary settings such as critical or emergency care 
is typically a shared process and thus more individuals might 
decline to proceed or continue with the research.
A prospective study of critically ill adults in 23 Canadian 
ICUs found that 57% of opportunities to recruit eligible 
patients into studies (mostly RCTs) are either missed or infea-
sible (1). In two U.S. studies, the proportion of missed oppor-
tunities was 69% (94 of 136) in an ICU (3) and 47% (563 of 
1,202) in a trauma center (4). Others have described lessons 
learned from acute care RCTs that were discontinued due to 
slow recruitment (5–10). Lack of substitute decision makers 
was the most common reason for slow recruitment in a trial 
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of acute lung injury (5), and inability to complete the recruit-
ment interview was the most common reason for slow recruit-
ment in a trial enrolling patients with palliative care needs in 
an emergency department (9). However, the frequency with 
which recruitment challenges actually lead to premature dis-
continuation of acute care RCTs in comparison to nonacute 
care RCTs is unknown.
The objective of this study was to compare the risk for trial 
discontinuation, in particular due to slow recruitment, in a large 
sample of acute and nonacute care RCTs approved by IRBs.
METHODS
Study Design and Sample
We conducted a retrospective cohort study using RCTs 
approved between 2000 and 2003 by six IRBs in Switzerland 
(Basel, Lucerne, Zurich, and Lausanne), Germany (Freiburg), 
and Canada (Hamilton). The IRBs were responsible for human 
research in large university centers and additional hospitals 
in their respective catchment areas. We approached the IRBs 
through existing contacts in order to acquire our convenience 
sample. To minimize the number of ongoing or unpublished 
RCTs, we focused on protocols that had been approved more 
than 10 years ago. For this analysis, we excluded protocols of 
RCTs that involved only healthy volunteers, RCTs that were 
never started, and RCTs that investigators reported as ongoing 
in our survey as of April 2013 (see below). The participating 
IRBs approved this study or explicitly stated that no formal 
ethical approval was necessary. A detailed study protocol (11), 
an analysis of the dataset describing the prevalence of discon-
tinued trials across medical specialties (12), and two ancillary 
analyses of the dataset (13, 14) are published elsewhere.
Definitions
Two researchers independently classified RCTs as acute care if 
they enrolled 1) patients receiving critical care irrespective of 
when acute symptoms occurred (critical care) or 2) emergency 
patients who received the study intervention within 24 hours 
of presentation with acute symptoms (emergency care). Dis-
agreements were resolved by discussion or consultation with 
a clinician who was familiar with the RCT topic. We did not 
consider an RCT as acute care if patients consented to surgical 
intensive care before they received elective surgery—that is, if 
the recruitment took place in a nonacute situation.
We considered an RCT discontinued if the investigators indi-
cated trial discontinuation in correspondence with IRBs, in jour-
nal publications, or in their response to our survey (see below). 
If still unclear, we additionally classified trials as discontinued 
if the actual sample size was less than a prespecified thresh-
old of 90% of the target sample size (for studies with known 
achieved and target sample size). Accordingly, we considered an 
RCT completed if at least 90% of the targeted sample size was 
recruited and the investigators did not indicate discontinuation. 
We recorded all reasons for trial discontinuation. If we could not 
elucidate the reason for RCT discontinuation, we classified the 
trial as discontinued due to unknown causes (11, 12).
Data Sources and Extraction
Reviewers trained in trial methodology abstracted 30% of 
RCT protocols independently and in duplicate using pretested 
forms with detailed written instructions and following formal 
calibration exercises with all data abstractors. Disagreements 
arising in duplicate review were resolved by discussion. Single 
investigators abstracted the remaining RCT protocols, with 
periodic duplicate agreement checks from a random sample of 
protocols at several points during the process.
We followed-up on the completion status and publication 
history of RCTs as of April 27, 2013 by using information 
from IRB files and by conducting comprehensive searches for 
corresponding publications in electronic databases and trial 
registries. If trial completion or publication status remained 
unclear, we surveyed the investigator by sending them a stan-
dardized questionnaire through the overseeing IRB. All cor-
responding publications were abstracted independently and 
in duplicate; disagreements were resolved by consensus or by 
third-party adjudication.
Statistical Analyses
We present trial discontinuation, reported reasons, and pub-
lication status as frequencies and percentages, stratified by 
acute care and nonacute care RCTs. We explored differences 
between acute and nonacute care RCTs by using chi-square or 
Fisher exact tests for proportions, t tests for normally distrib-
uted, and rank sum tests for non-normally distributed con-
tinuous variables. We considered two-tailed p value less than 
or equal to 0.05 statistically significant and did not correct for 
multiple testing.
We investigated possible factors associated with RCT dis-
continuation due to slow recruitment by using multivariable 
logistic regression. As prespecified (11, 12), we limited our 
regression analysis to completed RCTs and RCTs discontin-
ued due to slow recruitment and excluded RCTs with other 
reasons for discontinuation. Assuming different recruitment 
and discontinuation patterns, we additionally excluded RCTs 
that were explicitly labeled as pilot RCTs (5 acute care and 46 
nonacute care) and RCTs that randomized clusters such as 
hospitals or families (0 acute care and 8 nonacute care RCTs) 
from our regression model. We investigate the incremental risk 
associated with acute care (vs nonacute care) after adjustment 
for previously examined prespecified protocol-level variables 
(11, 12): investigator sponsorship (vs industry), planned sam-
ple size (in decrements of 100), center status (multicenter vs 
single center), crossover design (vs parallel), type of control 
intervention (active control vs placebo or nonactive interven-
tion), any reported method to predict recruitment rate (vs 
no method reported), and methodologic or logistic support 
from a contract research organization or clinical trial unit (vs 
no support reported). In addition, we adjusted for pediatric 
RCTs (vs adult), another setting-specific potential risk factor 
for slow recruitment (11). The event-to-variable ratio was 10 
(90 discontinuations due to slow recruitment and 9 explana-
tory variables). We conducted a complete case analysis and 
sensitivity analyses by using multiple imputations for missing 
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information about trial discontinuation (missing in 5 acute 
and 66 nonacute care RCTs), reasons for discontinuation 
(missing in 1 acute and 24 nonacute care RCTs), and sample 
size (missing in 1 acute and 11 nonacute care RCTs) (15).
RESULTS
RCT Characteristics
We included 894 RCTs in the analysis (Fig. 1). Of those, 64 (7%) 
recruited patients in an acute care setting and 830 recruited patients 
in a nonacute care setting. The 64 acute care RCTs included 29 
critical care RCTs (17 adult and 12 pediatric) and 35 emergency 
care RCTs (14 stroke trials, 13 acute coronary syndrome trials, and 
8 others). Nonacute RCTs included four postsurgical critical care 
trials for which patients consented preoperatively and three RCTs 
that recruited emergency care patients but started the interven-
tion not within 24 hours (all 48 hr or later).
Most characteristics of critical and emergency care RCTs 
were similar (Table 1). Critical care RCTs had on average a 
shorter follow-up (median 0.9 vs 3.0 mo; p = 0.032), were less 
frequently labeled as pilot trial (0% vs 17%; p = 0.028), were 
less frequently sponsored by industry (41% vs 71%; p = 0.030), 
and more frequently enrolled children (41% vs 3%; p < 0.001) 
than emergency care RCTs.
Acute care RCTs as compared with nonacute care RCTs 
had a slightly larger planned sample size (median 300 vs 260; 
p = 0.023), a shorter planned follow-up (median 2.8 vs 6 mo; 
p < 0.001), were more frequently overseen by a data safety and 
monitoring board (DSMB) (56% vs 27%; p < 0.001), more fre-
quently had planned interim analyses (47% vs 31%; p = 0.015), 
more frequently included a placebo or no-treatment arm (78% 
vs 58%; p = 0.003), more frequently enrolled children (20% vs 
9%; p = 0.005), and less frequently reported quality of life as 
predefined outcome (11% vs 38%; p < 0.001). The remaining 
characteristics did not differ significantly between acute and 
nonacute care RCTs (Table 1).
Of the 64 acute care RCTs, 37 (58%) were published as a 
peer-reviewed journal article, 6 (9%) in abstract format only, 
and 21 (33%) were not published at a median follow-up of 
11.6 years from IRB approval. The respective publication rates 
in the 830 nonacute care RCTs were similar: 493 (59%) peer-
reviewed journal articles, 50 (6%) abstracts, and 286 (35%) 
not published (difference not formally tested, see Discussion 
section). The year of publication ranged from 2001 to 2013, 
with a median in 2006. Confidentiality agreements with col-
laborating IRBs do not allow us to provide a list of references 
of all included RCT publications.
Discontinuation
Of the 894 RCTs, 575 (64%) were completed and 249 (28%) 
were discontinued prior to enrolling the target sample, and 
the completion status remained unclear in 71 RCTs (8%) 
(Table 2). We determined RCT discontinuation from the pub-
lication alone (61 of 249, 25%), the survey alone (69 of 249, 
28%; response rate 80%), IRB file alone (67 of 249, 27%), com-
bined sources (27 of 249, 11%), or because the actual sample 
size was less than 90% of the target sample size (25 of 249, 
10%, including one acute care trial).
Acute care RCTs were more frequently discontinued 
(28 of 64, 44%) than nonacute care RCTs (221 of 830, 27%; 
p = 0.004). Unknown com-
pletion status was balanced 
between settings. Slow recruit-
ment was the most frequent 
reason for discontinuation, 
both in acute care (13 of 64, 
20%) and nonacute care RCTs 
(87 of 830, 11%) (Table 2). 
Multivariable logistic regres-
sion identified acute care RCTs 
as an independent incremental 
risk factor for discontinua-
tion due to slow recruitment 
(adjusted odds ratio [OR], 
4.00; 95% CI, 1.72–9.31). 
Investigator sponsorship (OR, 
4.45; 95% CI, 2.59–7.65) and 
small planned sample size 
(OR, 1.05; 95% CI, 1.01–1.09, 
in decrements of 100) were 
also significantly associated 
with discontinuation due to 
slow recruitment (Table 3). 
Multiple imputations for miss-
ing information regarding trial 
discontinuation and sample 
Figure 1. Trial flow diagram illustrating sample generation. IRB = institutional review board, RCT = randomized 
clinical trial.
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TAbLE 1. Characteristics of Acute Care and Nonacute Care Randomized Clinical Trials
RCT Characteristics
Critical Care  
(n = 29)
Emergency Care  
(n = 35)
Total Acute Care  
(n = 64)
Total Nonacute Care  
(n = 830)
Planned target sample size, median (IQR) 235 (175–680) 400 (153–2,080) 300 (158–1,200) 260 (100–600)
Planned centers (%)
  Multiple 23 (79) 30 (86) 53 (83) 688 (83)
  Single 6 (21) 5 (14) 11 (17) 138 (17)
  Unclear 0 0 0 4 (0.5)
Unit of randomization (%)
  Individuals 29 (100) 35 (100) 64 (100) 815 (98)
  Clusters 0 0 0 12 (1)
  Body parts 0 0 0 3 (0.4)
Pediatric trial (%) 12 (41) 1 (3) 13 (20) 73 (9)
Study design (%)
  Parallel 26 (90) 34 (97) 60 (94) 776 (94)
  Crossover 2 (7) 0 2 (3) 39 (5)
  Factorial 1 (3) 1 (3) 2 (3) 13 (2)
  Unclear 0 0 0 2 (0.2)
Study purpose (%)
  Superiority 25 (86) 30 (86) 55 (86) 597 (72)
  Noninferiority 3 (10) 3 (7) 6 (9) 133 (16)
  Unclear 1 (3) 2 (6) 3 (5) 100 (12)
Research ethics committee (%)
  Basel 3 (10) 11 (31) 14 (22) 207 (25)
  Hamilton 9 (31) 10 (29) 19 (30) 159 (19)
  Freiburg 6 (21) 7 (20) 13 (20) 259 (31)
  Lausanne 6 (21) 5 (14) 11 (17) 138 (17)
  Zürich 5 (17) 1 (3) 6 (9) 37 (5)
  Lucerne 0 1 (3) 1 (2) 30 (4)
  Labeled as pilot RCT 0 6 (17) 6 (9) 63 (8)
  Industry sponsorship 12 (41) 25 (71) 37 (58) 514 (62)
Comparison group(s) (%)
  Included placebo or no treatment (often add-on RCTs) 24 (83) 26 (74) 50 (78) 483 (58)
  Active comparator(s) only 5 (17) 9 (26) 14 (22) 347 (42)
Data safety and monitoring board mentioned (%) 12 (41) 24 (69) 36 (56) 221 (27)
Stopping rule mentioned (%) 5 (17) 9 (26) 14 (22) 141 (17)
Interim analysis mentioned (%) 14 (48) 16 (46) 30 (47) 259 (31)
Follow-up, months from randomization, median (IQR) 0.9 (0.9–5.9) 3.0 (1.0–12.0) 2.8 (0.9–6.0) 6.0 (2.5–13.0)
Method to predict recruitment rate mentioned (%) 7 (24) 2 (6) 9 (14) 72 (9%)
Pilot study including informed consent (%) 3 (10) 0 3 (5) 8 (1)
Reported methodologic/logistic support (%) 11 (38) 18 (51) 29 (45) 357 (43)
Primary outcome specified (%) 24 (83) 31 (89) 55 (86) 778 (94)
Quality of life outcome planned (%) 3 (10) 4 (11) 7 (11) 312 (38)
RCT	=	randomized	clinical	trial,	IQR	=	interquartile	range.
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size did not alter the results (Supplemental Digital Content 1, 
http://links.lww.com/CCM/B501).
Of the 31 completed acute care RCTs, 27 (87%) were pub-
lished as peer-reviewed journal articles or abstracts, and the 
primary outcome was statistically significant in 13 of 27 (41%) 
publications. Of the 28 discontinued acute care RCTs, 15 (54%) 
were published as peer-reviewed journal articles or abstracts, and 
all reported that the primary outcome was not statistically signifi-
cant. Of the five RCTs with unclear completion status, one was 
published with a nonsignificant result for the primary outcome.
Of the 15 acute care RCTs discontinued due to slow recruit-
ment, 7 were subsequently published (in peer-reviewed jour-
nals) and 3 reported causes for slow recruitment. In the first 
trial, unforeseeable changes in the regulatory environment 
TAbLE 2. Completion Status and Reasons of Discontinuation of Acute and Nonacute Care 
Randomized Clinical Trials
Completion Status and  
Reasons For Discontinuation
Critical Care 
(n = 29)
Emergency Care 
(n = 35)
Total Acute Care 
(n = 64)
Total Nonacute Care  
(n = 830)
Completion status (%)
  Completed 12 (41) 19 (54) 31 (48) 544 (66)
  Discontinued 14 (48) 14 (40) 28 (44) 221 (27)
  Unclear 3 (10) 2 (6) 5 (8) 66 (8)
Reason for discontinuation (%)
  Slow recruitment 6 (21) 7 (20) 13 (20) 87 (11)
  Futility 3 (10) 4 (11) 7 (11) 30 (4)
  Benefit/harm 2 (7) 0 2 (3) 31 (4)
  Othera 2 (7) 3 (9) 5 (8) 49 (6)
  Unknown reason 1 (3) 0 1 (2) 24 (3)
a Included	other	reasons	such	as	administrative,	strategic,	or	financial.
TAbLE 3. Risk Factors for Discontinuation Due to Slow Recruitment
Protocol Characteristics
Discontinued  
Due to Slow  
Recruitment  
(n = 90)a
Completed  
(n = 526)a
Univariable Effect Multivariable Effect
OR (95% CI) p
Adjusted OR  
(95% CI) p
Acute care RCT (vs nonacute 
care) (%)
12 (13) 27 (5) 2.97 (1.44–6.14) 0.003 4.00 (1.72–9.31) 0.002
Investigator sponsorship  
(vs industry) (%)
59 (66) 158 (30) 4.43 (2.76–7.12) < 0.001 4.45 (2.59–7.65) < 0.001
Smaller sample size, median 
(interquartile range)
180 (80–320) 364 (155–800) 1.06 (1.01–1.11)b 0.010 1.05 (1.01–1.09)b < 0.001
Multicenter status (vs single 
center) (%)
71 (79) 470 (89) 0.46 (0.26–0.84) 0.011 1.80 (0.85–3.82) 0.12
No methodologic/logistic support 
reported (vs reported) (%)
62 (69) 279 (53) 1.94 (1.2–3.14) 0.007 1.49 (0.86–2.56) 0.088
Active control (vs placebo/no 
active control) (%)
37 (41) 204 (39) 1.14 (0.72–1.79) 0.58 1.37 (0.83–2.24) 0.22
Crossover design (vs parallel) (%) 8 (9) 21 (4) 2.61 (1.11–6.17) 0.028 2.18 (0.82–5.79) 0.13
No method to predict recruitment 
reported (vs reported) (%)
78 (87) 486 (92) 0.53 (0.27–1.06) 0.073 1.15 (0.52–2.54) 0.74
Pediatric RCT (vs adult) (%) 13 (14) 44 (8) 1.95 (1.00–3.81) 0.049 1.22 (0.57–2.63) 0.61
OR	=	odds	ratio,	RCT	=	randomized	clinical	trial.
a We	limited	the	analysis	to	RCTs	discontinued	for	slow	recruitment	and	completed	RCTs	and	excluded	51	pilot	RCTs	and	8	RCTs	that	randomized	clusters	(see	
Methods	section	for	a	rationale).	We	excluded	71	RCTs	with	missing	discontinuation	information,	25	RCTs	with	missing	reasons	for	discontinuation,	and	12	
RCTs	with	missing	sample	size	information.
b	In	decrements	of	100.
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precluded the participation of several countries. In the sec-
ond trial, the doubt among recruiting physicians regarding 
clinical equipoise of the treatment arms and their discomfort 
in approaching substitute decision makers caused the slow 
recruitment. In the third trial, slow recruitment was a result 
of the complex study protocol—specifically, logistic chal-
lenges related to patient transfer and lack of eligible patients 
due to overly strict inclusion criteria—and poor motivation of 
recruiting physicians who perceived a conflict of interest.
DISCUSSION
In a sample of 894 RCT protocols approved by one of the 
six IRBs from Switzerland, Germany, and Canada, 64 stud-
ies (7%) enrolled patients in an acute care setting. Investiga-
tors of almost half (28 of 64, 44%) of the acute care RCTs 
indicated early discontinuation, and the most commonly 
reported reason for discontinuation (20%) was slow recruit-
ment. The risk for discontinuation due to slow recruitment 
was approximately four-fold higher in acute than in non-
acute care RCTs.
This increased risk may result from recruitment challenges 
that are specific to the acute care setting (e.g., narrow time win-
dows or unavailability of substitute decision makers), a higher 
frequency of general recruitment challenges that are not spe-
cific to the acute care setting (e.g., untested eligibility criteria, 
lack of equipoise for the research, or overly complex study 
protocol) (16), or a combination of both setting-specific and 
nonspecific challenges. However, publications rarely reported 
causes for slow recruitment, and we were therefore unable 
to determine the relative impact of specific and nonspecific 
causes on the increased risk of trial discontinuation due to 
slow recruitment in acute care RCTs.
Only a minority of RCT protocols specified strategies to mit-
igate recruitment challenges such as support by a clinical trial 
unit and measures to sustain recruitment. Furthermore, only 
14% of acute and 9% of nonacute care RCT protocols specified 
a method to predict patient recruitment over time. Of those, 
very few based their prediction on data from a pilot study that 
included an informed consent process. The remainder pre-
dicted recruitment using retrospective or prospective screening 
for eligible patients, which are unreliable methods (16, 17). Rare 
specification of recruitment strategies (since these are often 
documented in internal trial documents such as operation 
manuals and likely underreported in trial protocols) and use of 
unreliable methods to predict recruitment may explain why our 
regression model did not identify a protective effect of explicit 
recruitment prediction on the prevention of slow recruitment.
Apart from the acute care setting, significant risk factors for 
trial discontinuation due to slow recruitment were small sam-
ple size and nonindustry sponsorship, which were factors we 
identified in a previous analysis (12). Larger RCTs may be bet-
ter organized (e.g., conduct by established research networks 
engaging multiple centers and collaboration among experi-
enced investigators), and industry-funded RCTs may be better 
resourced to address the problem of slow recruitment versus 
investigator-initiated trials.
Investigators of acute care RCTs more frequently reported 
a DSMB and more frequently specified interim analyses in the 
protocol than investigators of nonacute care trials. This could 
suggest that trialists in the acute care setting were more sen-
sitized to monitor early evidence of benefit, harm, or futility 
in vulnerable populations or simply reflect the tradition of 
DSMB oversight in trials of acute care interventions.
Strengths of our study include collaboration with six IRBs 
from three countries to document the history of 894 planned 
RCTs. We had full access to the files of all RCTs approved during 
a 3-year period, which provides additional safeguards against 
selection bias. We systematically searched all documents and 
contacted the authors to capture any relevant information 
about the course of the RCT. We involved trained methodolo-
gists to identify eligible studies and abstract data, following 
pretesting and calibration exercises (11). To minimize chance 
associations, we considered only a limited number of variables 
in our statistical model and conducted sensitivity analyses 
using multiple imputations for missing data.
Our study is limited by the reporting quality of the original 
RCT protocols and reports, which did not always transpar-
ently indicate factors that can predispose to trial discontinu-
ation due to slow recruitment (e.g., the extent of preparatory 
or pilot work, logistic barriers, financial, or nonfinancial 
incentives). We used single data extraction for almost 70% 
of protocols, thereby potentially increasing extraction errors. 
However, we used prepiloted extraction forms with detailed 
written instructions, conducted formal calibration exercises 
with all data extractors, and checked extractions from a ran-
dom sample of protocols at several points during the process. 
Agreement was good with no more than two discrepancies in 
answers to 30 main questions of the extraction form. All out-
come data on discontinuation and publication of RCTs were 
verified by a second investigator. Our comparison of acute 
care versus nonacute care RCTs is based on protocols that were 
approved by IRBs more than 10 years ago. Results might differ 
if more recent trials were analyzed. However, discontinuation 
due to recruitment challenges for RCTs in acute care is likely to 
remain. Collaborating with six IRBs in three countries increases 
the generalizability of our results, but findings may differ 
among RCTs performed in other jurisdictions where unique 
trial completion challenges exist, such as developing countries. 
Furthermore, although we reported risk factors for nonpub-
lication in our analysis of the full RCT cohort (12), namely 
early trial discontinuation, industry sponsorship, single-center 
trial, and small sample size, we did not test whether risk fac-
tors differ between acute and nonacute care RCTs; appropriate 
tests for interaction would have low power to either identify or 
exclude such differences. However, we do not expect risk fac-
tors for nonpublication to differ substantially between acute 
and nonacute care RCTs.
Our work provides the basis to test interventions aimed at 
limiting early discontinuation of acute care trials. We believe 
that interventions should primarily focus on the prevention 
of slow recruitment because it was the most frequent reason 
for discontinuation. Multicenter pilot randomized trials that 
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apply the full recruitment protocol could be part of the solu-
tion—they represent an opportunity to identify important 
barriers for recruitment such as lack of eligible patients, dif-
ficulties obtaining informed consent, doubt among recruit-
ing physicians regarding clinical equipoise of the treatment 
arms, or prohibitively complex protocols. A necessary feature 
of such pilot trials would be to include the same screening 
and informed consent processes as in the main trial. Further 
research is necessary to estimate the optimal size and dura-
tion of such pilot trials and the number and type of centers in 
which the pilot trial should be conducted to obtain the most 
stable recruitment estimates. Another possible solution would 
be to develop reliable prediction models for recruitment per-
formance (18). In addition, ongoing attention to recruitment 
trends, and introduction of strategies to sustain, bolster, or 
accelerate recruitment when necessary (19), is also imperative 
for acute care trialists once RCTs are underway.
CONCLUSIONS
Acute care RCTs are more vulnerable to premature discon-
tinuation than nonacute care RCTs and have an approxi-
mately four-fold higher risk of discontinuation specifically 
due to slow recruitment. These results highlight the need 
to develop strategies to reliably prevent and resolve slow 
patient recruitment in RCTs conducted in the critical and 
emergency care setting.
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